PULMONER ARTERİYEL HİPERTANSİYON TEDAVİSİNDE GÜNCEL YAKLAŞIMLAR

Amaç: Pulmoner arteriyel hipertansiyon (PAH), yüksek morbidite ve mortaliteye sahip kronik bir hastalıktır. PAH için uygulanan tedavi stratejileri hastaların yaşam kalitesinin iyileşmesini sağlamakla birlikte, hastaların büyük çoğunluğu için PAH, tedavi olasılığı olmayan hayatı sınırlayan bir hastalık olmaya devam etmektedir. Mevcut PAH tedavisinde karşılaşılan en önemli sorunlar hasta uyuncunun düşük olması ve yan etkilerin görülmesidir. Bu derlemede, PAH tedavisinde rhoA/rho kinaz, tirozin kinaz, endotel progenitör hücreleri, vazoaktif bağırsak peptiti ve miRNA gibi çeşitli yeni moleküler yolakların potansiyeli tartışılmıştır. Ayrıca, tedavide kullanılmak üzere onaylanmış ve inceleme aşamasında olan etkin maddelerin etkinliğini artırmak için hedeflendirilmiş ilaç taşıyıcı sistemlerin kullanımına yönelik çeşitli yöntemler değerlendirilmiştir.

CURRENT APPROACHES IN PULMONARY ARTERIAL HYPERTENSION TREATMENT

Objective: Pulmonary arterial hypertension (PAH) is a cronic disease with high morbidity and mortality. Although the applied treatment strategies provide an improvement in the quality of life of the patients, PAH continues to be a life-limiting disease for most patients, without the possibility of treatment. The most important problems encountered in the current therapies for PAH are patient incompliance and off-target side effects. In this review, the potential of various new molecular pathways such as rhoA/rho kinase, tyrosine kinase, endothelial progenitor cells, vasoactive intestinal peptide and miRNA are discussed in the treatment of PAH. In addition, various methods for the use of targeted drug delivery systems have been evaluated to improve the efficacy of approved and investigational drugs.

Keywords:

Drug delivery systems, pulmonary arterial hypertension targeted therapy, treatment strategies,

PDF

___

1. Zolty, R. (2020). Pulmonary arterial hypertension specific therapy: The old and the new. Pharmacology & Therapeutics, 214(2020), 1-18.
2. Galie, N., Humbert, M., Vachiery, J., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Noordegraaf, A.V., Beghetti, M., Ghofrani, A., Sanchez, M.A.G., Hansmann, G., Klepetko, W., Lancellotti, P., Matucci, M., McDonagh, T., Pierard, L.A., Trindade P.T., Zompatori, M., Hoeper, M. (2016). Guidelines on diagnosis and treatment of pulmonary hypertension. European Heart Journal, 37, 67-119.
3. Türk Toraks Derneği Web site. Retrieved February 5, 2020. from https://www.toraks.org.tr/halk/News.aspx?detail=2180
4. Öztürk, Ö., Şahin, Ü. (2009). Pulmoner hipertansiyon: Tanı ve tedavisi. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 16 (1), 39-47.
5. Demir, R., Küçükoğlu, M.S. (2010). Pulmoner arter hipertansiyonunda egzersiz kapasitesinin değerlendirilmesi. Türk Kardiyoloji Derneği Arşivi, 38(8), 580-588.
6. Vaidya, B., Gupta, V. (2015). Novel therapeutic approaches for pulmonary arteriel hypertension: Unique molecular targets to site-specific drug delivery. Journal of Controlled Release, 211, 118- 133.
7. Gunt, C., Çekmen, N. (2016). Pulmoner hipertansiyon ve weaning. Türk Yoğun Bakım Dergisi, 14, 68-79.
8. Spiekerkoetter, E., Kawut, S.M., de Jesus Perez, V.A. (2019). New and emerging therapies for pulmonary arterial hypertension. Annual Review of Medical, 70, 45-59.
9. Çörtük, M., Çetinkaya, E. (2017). Pulmoner arteriyel hipertansiyonda prostasiklin analogları ve prostaglandin reseptör agonistleri. Türkiye Klinikleri Akciğer Arşivi, 18(1), 17-24.
10. Kılıçkesmez, K., Küçükoğlu, M.S. (2010). Pulmoner arteriyel hipertansiyon tedavisinde fosfodiesteraz-5 inhibitörleri. Anadolu Kardiyoloji Dergisi, 10(2), 16-18.
11. Gessler, T. (2018). Inhalation of repurposed drugs to treat pulmonary hypertension. Advanced Drug Delivery Reviews, 133, 34-44.
12. O’Connell, C., Amar, D., Boucly, A., Savale, L., Jais, X., Chaumais, M., Montani, D., Humbert, M., Simonneau, G., Sitbon, O. (2016). Comparative safety and tolerability of prostacyclins in pulmonary hypertension. Drug Safety, 39, 287-294.
13. Ishihara, T., Hayashi, E., Yamamoto S., Kobayashi, C., Tamura, Y., Sawazaki, R., Tamura, F., Tahara, K., Kasahara, T., Ishihara, T., Takenaga, M., Fukuda, K., Mizushima, T. (2015). Encapsulation of beraprost sodium in nanoparticles: Analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension. Journal of Controlled Release, 197, 97–104.
14. Leifer, F.G., Konicek, D.M., Chen, K., Plaunt, A.J., Salvail, D., Laurent, C.E., Corboz, M.R., Li, Z., Chapman, R.W., Perkins, W.R., Malinin, V.S. (2018). Inhaled treprostinil-prodrug lipid nanoparticle formulations provide long-acting pulmonary vasodilation. Drug Research, 68 (11), 605-614.
15. Jain, P.P., Leber, R., Nagaraj, C., Leitinger, G., Lehofer, B., Olschewski, H., Olschewski, A., Prassl, R., Marsh, L.M. (2014). Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries. International Journal of Nanomedicine, 9, 3249-3261.
16. Alwan, R.M., Raja, N.A., Alhagiesa, A.W. (2020). Formulation and optimization of lyophilized selexipag nanocrystals to ımprove the saturation solubility and dissolution rate. Systematic Reviews in Pharmacy, 11(11), 596-605.
17. Mirici, A., Gönlügür, U. (2011). Pulmoner hipertansiyonda medikal tedavi. Nobel Medicus, Cilt 7(1), 5-11.
18. Segura-Ibarra, V., Wu, S., Hassan, N., Moran-Guerrero, J.A., Ferrari, M., Guha, A., KarmoutyQuintana, H., Blanco, E. (2018). Nanotherapeutics for treatment of pulmonary arterial hypertension. Frontiers in Physiology, 9:890, 1-16.
19. Anjaneyulu, V., Gnanaprakash, K., Chandrasekhar, K.B. (2014). Development and evaluation of bosentan pulsincap formülation for controlled release. International Journal of Pharmaceuticals and Health Care Research, 2(2), 109-114.
20. Deshmane, S., Deshmena, S., Shelke, S., Biyani, K. (2018). Enhancement of solubility and bioavailability of ambrisentan by solid dispersion using Daucus carota as a drug carrier: formulation, characterization, in vitro, and in vivo study. Drug Development and Industrıal Pharmacy, 44(6), 1001-1011.
21. Hill, N.S., Preston, I.R., Roberts, K.E. (2015). Inhaled therapies for pulmonary hypertension. Respiratory Care, 60(6), 794-805.
22. Selimoğlu Şen, H. (2015). İdyopatik pulmoner arter hipertansiyonu tedavisi: Güncel durum ve gelecekteki yönelişler. Güncel Göğüs Hastalıkları Serisi, 3(1), 100-118.
23. Shahin, H.I., Vinjamuri, B.P., Mahmoud, A.A., Shamma, R.N., Mansour, S.M., Ammar, H.O., Ghorab M.M., Chougule, M.B., Chablani, L. (2019). Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension. Journal of Controlled Release, 302, 126-139.
24. Lila, A.S.A., Gomaa, E., Ghazy, F.E.S., Hasan, A.A. (2020). Treatment of pulmonary arterial hypertension by vardenafil-solid dispersion lozenges as a potential alternative drug delivery system. Journal of Drug Delivery Science and Technology,55:101444, 1-7.
25. Rad, R.T., Dadashzadeh, S., Vatanara, A., Alavi, S., Ghasemian, E., Mortazavi, S.A. (2019). Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment. European Journal of Pharmaceutical Sciences, 133, 275-286.
26. Başkurt, M., Küçükoğlu, M.S. (2010). Pulmoner arteriyel hipertansiyon tedavisinde prostanoidler. Anadolu Kardiyoloji Dergisi, 10(2), 2-8.
27. Galiè, N., Palazzini, M., Leci, E., Manes, A. (2010). Current therapeutic approaches to pulmonary arterial hypertension. Revista Española de Cardiología, 63(6), 708-24.
28. Hoeper, M.M., Dinh-Xuan, A.T. (2004). Combination therapy for pulmonary arterial hypertension: Still more questions than answers. European Respiratory Journal, 24, 339-340.
29. Okutucu, S., Tokgözoğlu, L. (2010). Güncel kılavuzlar ışığında pulmoner hipertansiyonda tedavi algoritmaları. Anadolu Kardiyoloji Dergisi, 10(2), 19-26.
30. Huertas, A., Tu, L., Guignabert, C. (2017). New targets for pulmonary arterial hypertension: Going beyond the currently targeted three pathways. Current Opinion in Pulmonary Medicine, 23(5), 377-385.
31. Duong-Quy, S., Bei, Y., Liu, Z., Dinh-Xuan, A.T. (2013). Role of rho-kinase and its inhibitors in pulmonary hypertension. Pharmacology & Therapeutics, 137, 352–364.
32. Pacaud, P., Loirand, G. (2010). Rho kinase inhibitors for pulmonary hypertension: Waiting for clinical evidence. European Respiratory Journal, 36, 709–711.
33. Barman, S.A., Zhu, S., White, R.E. (2009). RhoA/Rho-kinase signaling: A therapeutic target in pulmonary hypertension. Vascular Health and Risk Management, 5, 663–671.
34. Gupta, V., Gupta, N., Shaik, I.H., Mehvar, R., McMurtry, I.F., Oka, M., Nozik-Grayck E., Komatsu, M., Ahsan, F. (2013). Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. Journal of Controlled Release, 167(2), 189-199.
35. Godinas, L., Guignabert, C., Seferian, A., Perros, F., Bergot, E., Sibille Y., Humbert, M., Montani, D. (2013). Tyrosine kinase inhibitors in pulmonary arterial hypertension: A doubleedge sword?. Seminars in Respiratory and Critical Care Medicine, 34, 714-724.
36. Alkhatib, Y., Albashaireh, D., Al-Aqtash, T., Awdish, R. (2016). The role of tyrosine kinase inhibitor ‘‘lapatinib’’ in pulmonary hypertension. Pulmonary Pharmacology & Therapeutics, 37, 81-84.
37. Akagi, S., Nakamura, K., Miura, D., Saito, Y., Matsubara, H., Ogawa, A., Matoba, T., Egashira, K., Ito, H. (2015). Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension. International Heart Journal, 56, 354-359.
38. Petkov, V., Mosgoeller, W., Ziesche, R., Raderer, M., Stiebellehner, L., Vonbank, K., Funk, G., Hamilton, G., Novotny, C., Burian, B., Block, L. (2003). Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. The Journal of Clinical Investigation, 111, 1339-1346.
39. Leuchte, H.H., Baezner, C., Baumgartner, R.A., Bevec, D., Bacher, G., Neurohr, C., Behr, J. (2008). Inhalation of vasoactive intestinal peptide in pulmonary hypertension. European Respiratory Journal, 32, 1289-1294.
40. Hajos, F., Stark, B., Hensler, S., Prassl, R., Mosgoeller, W. (2008). Inhalable liposomal formulation for vasoactive intestinal peptide. International Journal of Pharmaceutics, 357, 286- 294.
41. Chen, H., Strappe, P., Chen, S., Wang, L. (2014). Endothelial progenitor cells and pulmonary arterial hypertension. Heart, Lung and Circulation, 23, 595-601.
42. Sun, H., Li, G., Du, Z., Bing, Z., Ji, Z., Luo, G., Pan, S. (2019). The relationship between endothelial progenitor cells and pulmonary arterial hypertension in children with congenital heart disease. BMC Pediatrics, 19(1), 1-6.
43. Diller, G., Thum, T., Wilkins, M.R., Wharton, J. (2010). Endothelial progenitor cells in pulmonary arterial hypertension. Trends in Cardiovascular Medicine, 20, 22-29.
44. Fadini, G.P., Avogaro, A., Ferraccioli, G., Agostini, C. (2010). Endothelial progenitors in pulmonary hypertension: New pathophysiology and therapeutic implications. European Respiratory Journal, 35, 418-425.
45. Nagaya, N., Kangawa, K., Kanda, M., Uematsu, M., Horio, T., Fukuyama, N., Hino, J., HaradaShiba, M., Okumura, H., Tabata, Y., Mochizuki, N., Chiba, Y., Nishioka, K., Miyatake, K., Asahara, T., Hara, H., Mori, H. (2003). Hybrid cell–gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation, 108, 889-895.
46. Rothman, A., Restrepo, H., Sarukhanov, V., Evans, W.N., Wiencek, R.G., Williams, R., Hamburger, N., Anderson, K., Balsara, J., Mann, D. (2017). Assessment of microRNA and gene dysregulation in pulmonary hypertension by endoarterial biopsy. Pulmonary Circulation, 2017, 7(2), 455-464.
47. Sun, M., Yang, Q. (2013). Role of microRNAs in hypoxia-induced pulmonary hypertension. Cardiovascular Pharmacology, 3(1),1-3.
48. Santulli, G. (2015). microRNA: Medical Evidence From Molecular Biology to Clinical Practice. Volume 888, Springer International Publishing, Switzerland, p.237.
49. Miao, C., Chang, J., Zhang, G. (2018). Recent research progress of microRNAs in hypertension pathogenesis, with a focus on the roles of miRNAs in pulmonary arterial hypertension. Molecular Biology Reports, 45, 2883-2896.
50. McLendon, J.M., Joshi, S.R., Sparks, J., Matar, M., Fewell, J.G., Abe, K., Oka, M., McMurtry, I.F., Gerthoffer, W.T. (2015). Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. Journal of Controlled Release, 210, 67-75.